No quarterly revenue total was found in Adicet Bio, Inc.'s SEC filings.
Adicet Bio, Inc. (ACET) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$20.0 million. As of Jun 30, 2026 it held $118.2 million in cash and investments and $12.9 million in total debt.
Revenue
—
Net income
$-21.36M
+31.6% vs year-ago quarter
Operating cash flow
$-19.82M
+25.6% vs year-ago quarter
Free cash flow
$-20.02M
+24.9% vs year-ago quarter
EPS
$-1.99
+63.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
9.36M
-88.8% vs year-ago quarter
Net cash
$105.34M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACET (Nasdaq)
- Fiscal year ends
- December 26
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1720580
- Former names
- resTORbio, Inc. (until Aug 21, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$22.3M | -$21.6M | -$31.9M | -$28.0M | -$32.4M |
| Net income | -$21.4M | -$20.2M | -$30.5M | -$26.9M | -$31.2M |
| Diluted EPS | -$1.99 | -$1.88 | $0.13 | -$0.29 | -$5.48 |
| Operating cash flow | -$19.8M | -$21.5M | -$20.9M | -$22.3M | -$26.6M |
| Free cash flow | -$20.0M | -$21.5M | -$20.9M | -$22.5M | -$26.7M |
| Total assets | $148.2M | $169.4M | $192.4M | $140.5M | $163.0M |
| Total liabilities | $28.0M | $29.3M | $33.1M | $31.3M | $29.6M |
| Stockholders' equity | $120.1M | $140.1M | $159.2M | $109.1M | $133.4M |
| Cash and investments | $118.2M | $137.6M | $158.5M | $103.1M | $125.0M |
| Total debt | $12.9M | $13.9M | $14.7M | $15.5M | $15.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 28, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 1, 2026 | Sep 1, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
All 682 Adicet Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.